An Open-Label Evaluation of the Independent Effects of Coadministration of a High-Fat Meal and Naltrexone Blockade on the Pharmacokinetic Profile of Dilaudid OROS (Hydromorphone HCI) 16mg

This study has been completed.

Study NCT00399295 Information provided by Alza Corporation, DE, USA

First Received: November 10, 2006 Last Updated: April 26, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	June 1997
Estimated Primary Completion Date:	No date given

No publications provided by Alza Corporation, DE, USA

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Sathyan G, Xu E, Thipphawong J, Gupta SK. Pharmacokinetic profile of a 24-hour controlled-release OROS formulation of hydromorphone in the presence and absence of food. BMC Clin Pharmacol. 2007 Feb 2;7:2.